Recently merged INC Research/inVentiv Health has now announced it has changed its brand identity to Syneos Health, Inc. 

The company explains that the word Syneos communicates the value of synchronizing clinical and commercial capabilities to accelerate customer performance. The name is also derived from “neo,” which the company says signals a new approach to problem-solving and a new biopharmaceutical solutions category for the healthcare workforce. 

“Syneos Health fully expresses our value proposition – that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialize their therapies,” said Alistair Macdonald, chief executive officer of Syneos Health. “Unlike traditional CROs and commercialization businesses, we are knocking down walls and enabling clinical and commercial experts to work in sync by using the latest technologies, advanced business practices and the advantages of scale. Our Biopharmaceutical Acceleration Model is unique to the industry, and from this ambitious vision, Syneos Health was born.”

In connection with the name change, Syneos Health common shares are expected to trade on the Nasdaq Global Select Market under the new ticker symbol “SYNH” by January 9, 2018. Until then, Syneos Health will continue to be listed under INC Research Holdings, Inc. and the symbol “INCR.”